| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-545 |
| filingDate |
2016-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2018502578-A |
| titleOfInvention |
Endonuclease targeting blood coagulation factor VIII gene and composition for treating hemophilia containing the same |
| abstract |
The present invention relates to a method for inducing the inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting the inversion of blood coagulation factor VIII gene in which the inversion has occurred, and the A type with the inversion corrected using the method. Provide induced universal stem cells derived from hemophilia patients. The method of the present invention efficiently studies the inversion of F8 gene intron 1 and intron 22 among the causes of severe type A hemophilia, thereby studying the pathogenesis of type A hemophilia. And useful as a research tool for therapeutic agent screening. Inverted-corrected induced universal stem cells produced by the method of the present invention can restore a genotype in which a mutation has occurred to a wild-type state, regardless of a normal method through a normal gene or protein transmission. Enables efficient and fundamental treatment for type A hemophilia. [Selection] Figure 1b |
| priorityDate |
2015-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |